Kerr Douglasinsider trades
In SEC Form 4 filings, Kerr Douglas is listed as Head of R&D and CMO of Dyne Therapeutics, Inc. (DYN). In the last 90 days, Kerr Douglas sold $115.5K of Dyne Therapeutics, Inc. (DYN) on the open market and bought none. All 2 sales were reported under a 10b5-1 trading plan.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| DYNDyne Therapeutics, Inc. | Head of R&D and CMO | 4 | Oct 22 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-08
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| DYNDyne Therapeutics, Inc. | Oct 20 | Oct 22 | A | 8,000 | $0.00 | $0 | 170,564 | No | Form 4 |
| DYNDyne Therapeutics, Inc. | Oct 20 | Oct 22 | A · derivative | 12,000 | $16.27 | $195,240 | 12,000 | No | Form 4 |
| DYNDyne Therapeutics, Inc. | Sep 8 | Sep 8 | S | 1,290 | $18.88 | Sale −$24,355 | 162,564 | Yes | Form 4 |
| DYNDyne Therapeutics, Inc. | Sep 4 | Sep 8 | S | 3,745 | $24.35 | Sale −$91,191 | 163,854 | Yes | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.